Preface
16
Spectra Optia Apheresis System Operator’s Manual
Fluids Administered During Apheresis Procedures
This section includes descriptions of fluids that may be used during apheresis procedures on the Spectra Optia
system. Before use, verify that the fluid has not expired by checking the expiration date printed on the package. Do
not use the item if the current date is past the expiration date.
Saline Solution
Use sterile 0.9% sodium chloride injection to prime the tubing set and to perform the procedure.
Anticoagulant
ACD-A
Each 100 mL of ACD-A contains 2.2 g sodium citrate hydrous, 730 mg citric acid anhydrous, and 2.45 g dextrose
hydrous.
Citrate toxicity
ACD-A can cause citrate toxicity in certain patients. Mild forms of this condition are generally recognized by
peripheral paresthesia, tingling sensations in the extremities, and/or restlessness. Severe forms of this condition can
result in significant cardiac dysfunction. Terumo BCT recommends that you frequently assess the condition of the
patient throughout the apheresis procedure.
Hydroxyethyl Starch (HES)
HES is a sedimenting agent that causes RBC to separate more efficiently from granulocytes during a collection
procedure. When using HES, you must add trisodium citrate to the HES for anticoagulation.
Replacement Fluids
Careful selection and use of appropriate replacement fluids contributes to the maintenance of the patient’s plasma
oncotic pressure and blood pressure. During TPE and depletion procedures, the patient response to decreasing
blood viscosity and plasma protein levels may vary and be difficult to predict. In addition, non-target cells may be
depleted and may require replacement. Therefore, the physician should prescribe the type and volume of
replacement fluid used. The prescription should consider the patient’s fluid status, protein balance, and other
pertinent factors that the physician believes could affect the patient’s condition.
SpectraOptiaOpsManual.book Page 16 Thursday, May 17, 2018 11:24 AM
